Compare Natera Inc. Common Stock (NTRA) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Western Union Co — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Western Union Co trades at $6.05 (market cap $1.90B). The key difference: Natera Inc. Common Stock is far larger — about 30× Western Union Co's market cap, and Western Union Co pays a 15.41% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Western Union Co for 96 Days on average.
| NTRA | WU | |
|---|---|---|
Market Cap | $57.03B | $1.90B |
Volume | 1,131,157 | 6,506,793 |
Sector | Health | Financials |
52-Week High | $425.64 | $10.28 |
52-Week Low | $179.42 | $5.90 |
Typical Hold Time | 0 Days | 96 Days |
Enterprise Value | $56.18B | $1.81B |
Dividend Yield | — | 15.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Western Union (WU) trades at $6.05, down 0.98% on the day and near its 52-week low of $6.00. The stock shows bearish technical signals with recent earnings misses in Q1 and Q2 2026. Fundamentally, WU maintains strong profitability with a 9.79% net margin and attractive valuation metrics including a P/E of 4.92. The company's $200 million cost-cutting initiative and Intermex acquisition aim to drive future growth despite revenue declines from $4.5B in 2022 to $4.05B in 2025.
WU presents a value opportunity with deep undervaluation but faces execution risks. The stock trades below analyst consensus target of $6.71, offering 11% upside potential. However, declining revenue trends, integration challenges from the Intermex acquisition, and competitive pressures in money transfer services create headwinds. Investor sentiment remains cautious with only 12% buy ratings from analysts, reflecting concerns about the company's digital transition and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
